Patients with cancer are at a higher risk of developing thromboembolic events due to the hypercoagulable state induced by the malignancy and its treatments. This makes the use of anticoagulants like heparin particularly important. Moreover, recent studies suggest that heparin may have direct antitumor effects, making it a topic of significant interest in oncology.
